Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 15/20 | 0.56 |
| ▸ | HRH1 | P35367 | 15/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27629332 | 0.95 | HRH2 (0.59) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL9047895 | 0.93 | HRH2 (0.60) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL11747160 | 0.93 | HRH2 (0.60) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL9051052 | 0.89 | ALDH1A1 (0.56) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL11392680 | 0.87 | HRH2 (0.55) | HRH2HRH1ALDH1A1POLBHTT | |
| Hydrochloric Acid SCHEMBL27445572 | 0.87 | ALDH1A1 (0.58) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL5537946 | 0.86 | HRH2 (0.53) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL3270714 | 0.86 | ALDH1A1 (0.59) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL10854255 | 0.86 | HRH2 (0.53) | HRH2HRH1ALDH1A1POLBHTT | |
| SCHEMBL12846943 | 0.85 | HRH2 (0.56) | HRH2HRH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| CN-1136191-C | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | ������ҩ������˾ | 2004-01-28 | — | — | CN | disclosed |
| CN-1301253-A | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | AVENTIS PHARMACEUTICAL INC (US) | 2001-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | HRH2 434/4885HRH1 700/4885ALDH1A1 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.